Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin
AbstractInfluenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Yang, J.; Li, M.; Shen, X.; Liu, S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses 2013, 5, 352-373.
Yang J, Li M, Shen X, Liu S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses. 2013; 5(1):352-373.Chicago/Turabian Style
Yang, Jie; Li, Minmin; Shen, Xintian; Liu, Shuwen. 2013. "Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin." Viruses 5, no. 1: 352-373.